Back to Search
Start Over
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
- Source :
-
Leukemia & Lymphoma . Aug2022, Vol. 63 Issue 8, p1771-1773. 3p. - Publication Year :
- 2022
-
Abstract
- In the non-inferiority designed ELEVATE RR study, which directly compared ibrutinib and acalabrutinib in R/R CLL patients, treatment discontinuations related to adverse events occurred less frequently in acalabrutinib-treated patients (15%) than in ibrutinib-treated patients (21%) [[19]]. More than twenty years ago, the tyrosine kinase inhibitor imatinib, used in the treatment of chronic-phase chronic myeloid leukemia (CML), heralded a new era of targeted oral treatments in hematology [[1]]. Current oncology practices should continue to develop standard procedures for patient education, the development, and sharing of treatment plans, and routine monitoring of patient adherence to oral antineoplastic therapies. We should also be mindful that good communication between healthcare professionals and patients is crucial to enable our CLL patients to obtain maximal benefit from therapy whilst toxicities are minimized [[21]]. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 63
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 158597622
- Full Text :
- https://doi.org/10.1080/10428194.2022.2087072